Ambryon Biosciences

pCMV_BE4max

Mammalian expression plasmid for the BE4max cytosine base editor: a CMV promoter drives BE4max (bpNLS, APOBEC1 deaminase, XTEN linker, Cas9 D10A nickase, two UGI domains, bpNLS), terminated by a bGH polyadenylation signal, on an ampicillin-resistance backbone. Deposited as Addgene #112093.

Characteristics

8,961 bp circular plasmid. The BE4max coding sequence is 5,562 bp including its stop codon; the Cas9 module carries the D10A nickase mutation and the editor carries a bipartite nuclear localization signal at each end.

Applications

Expressing the BE4max cytosine base editor (rAPOBEC1-based, Cas9 D10A nickase, two UGI domains) by transfection in mammalian cells. Other groups used Addgene #112093 as follows. (1) As the rA1-CBE in HEK293T cells, cotransfected with sgRNA and anti-deaminase proteins (Ade) at a 1:1:1 plasmid ratio; the rA1-CBE was not inhibited by the Ades tested (Nat Commun 2022, 10.1038/s41467-022-28300-0). (2) As the template for BE4max mRNA: the CMV-driven coding sequence, which carries a T7 promoter, was subcloned with a WPRE and poly(A), linearized and transcribed in vitro; the mRNA was electroporated into human primary T cells and CD34+ hematopoietic stem and progenitor cells (HSPCs) with a B2M-targeting gRNA. BE4max produced 80-90% B2M-knockout cells in primary T cells, and in HSPCs it caused excess indels and reduced long-term engraftment compared with ABE8.20-m (Nat Biotechnol 2023, 10.1038/s41587-023-01915-4). (3) As the backbone of p2T-CMV-BE4max-BlastR, a modified BE4max plasmid with a blasticidin resistance cassette flanked by Tol2 transposon sequences, which expressed BE4 variants with SpCas9-PAM variants in HEK293T library cells (Nat Biotechnol 2020, 10.1038/s41587-020-0412-8). (4) As a comparator purchased from Addgene: in a GFP-disruption reporter assay BE4max showed no activity, while the MEGA-4 editor of that study did (Nucleic Acids Res 2023, 10.1093/nar/gkad1118). A fifth paper (Nat Commun 2022, 10.1038/s41467-022-30514-1) compares its NBE4max architecture (UGI moved to the N-terminus of rAPOBEC1) with BE4max and reports similar editing efficiencies; it does not state the plasmid used.

Payload18 features

in a 8,961 bp deposit · 12 features outside the design

0200040006000pCMV_BE4maxPlasmid DNA · 54% GCCMV promoter · promoter · 650–853 · 204 bpCMV promoterT7 promoter · promoter · 895–913 · 19 bpT7 promoterSV40 NLS · CDS · 963–983 · 21 bpSV40 NLSAPOBEC-1 · CDS · 984–1,667 · 684 bpAPOBEC-1Cas9(D10A) · CDS · 1,764–5,864 · 4,101 bpCas9(D10A)Cas9 · CDS · 1,764–5,864 · 4,101 bpCas9UGI · CDS · 5,895–6,143 · 249 bpUGIUGI · CDS · 6,174–6,422 · 249 bpUGISV40 NLS · CDS · 6,465–6,485 · 21 bpSV40 NLS6xHis · CDS · 6,494–6,511 · 18 bp6xHisbGH poly(A) signal · polyA signal · 6,540–6,764 · 225 bpbGH poly(A) signalCMV enhancer · enhancer · 270–649 · 380 bpCMV enhancerBE4max · CDS · 927–6,488 · 5,562 bpBE4maxCMV enhancer and promoter · promoter · 286–874 · 589 bpCMV enhancer and…0100020003000400050006000pCMV_BE4maxPlasmid DNA · 54% GCCMV promoter · promoter · 650–853 · 204 bpCMV promoterT7 promoter · promoter · 895–913 · 19 bpT7 promoterSV40 NLS · CDS · 963–983 · 21 bpSV40 NLSAPOBEC-1 · CDS · 984–1,667 · 684 bpAPOBEC-1Cas9(D10A) · CDS · 1,764–5,864 · 4,101 bpCas9(D10A)Cas9 · CDS · 1,764–5,864 · 4,101 bpCas9UGI · CDS · 5,895–6,143 · 249 bpUGIUGI · CDS · 6,174–6,422 · 249 bpUGISV40 NLS · CDS · 6,465–6,485 · 21 bpSV40 NLS6xHis · CDS · 6,494–6,511 · 18 bp6xHisbGH poly(A) signal · polyA signal · 6,540–6,764 · 225 bpbGH poly(A) signalCMV enhancer · enhancer · 270–649 · 380 bpCMV enhancerBE4max · CDS · 927–6,488 · 5,562 bpBE4maxCMV enhancer and promoter · promoter · 286–874 · 589 bpCMV enhancer and promot…0100020003000400050006000pCMV_BE4maxPlasmid DNA · 54% GCCMV promoter · promoter · 650–853 · 204 bpCMV promoterT7 promoter · promoter · 895–913 · 19 bpT7 promoterSV40 NLS · CDS · 963–983 · 21 bpSV40 NLSAPOBEC-1 · CDS · 984–1,667 · 684 bpAPOBEC-1Cas9(D10A) · CDS · 1,764–5,864 · 4,101 bpCas9(D10A)Cas9 · CDS · 1,764–5,864 · 4,101 bpCas9UGI · CDS · 5,895–6,143 · 249 bpUGIUGI · CDS · 6,174–6,422 · 249 bpUGISV40 NLS · CDS · 6,465–6,485 · 21 bpSV40 NLS6xHis · CDS · 6,494–6,511 · 18 bp6xHisbGH poly(A) signal · polyA signal · 6,540–6,764 · 225 bpbGH poly(A) signalCMV enhancer · enhancer · 270–649 · 380 bpCMV enhancerBE4max · CDS · 927–6,488 · 5,562 bpBE4maxCMV enhancer and promoter · promoter · 286–874 · 589 bpCMV enhancer and promoter

Sequence6,834 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Koblan et al. (2018). Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat Biotechnol — Koblan 2018 BE4max

Identifiers & revision